SOURCE: Bacilligen

June 17, 2008 09:40 ET

Bacilligen, Inc. to Present at BIO 2008 International Convention

ROCKVILLE, MD--(Marketwire - June 17, 2008) - Bacilligen, Inc., an early-stage biotechnology company located in Rockville, Maryland, announced today it is presenting at the BIO 2008 International Convention taking place June 17-20th in San Diego, California. Dr. Steve Bende, President and CEO of Bacilligen, will disclose information about the Company's technologies during the Business Forum, a 4-day partnering component of the conference. Dr. Bende is scheduled to present Thursday, June 19th, at 3 PM in Room 5B focusing on the company's improved bladder cancer therapy, rMB, and its novel vaccine vector platform, BVS.

About Bacilligen, Inc.

Bacilligen is a privately held biotechnology company focused on the development of recombinant mycobacteria, rMB, as an improvement to BCG cancer immunotherapy, as well as a novel bacteriophage capsid vector system, BVS, for the delivery of vaccines. Bacilligen's BVS possesses safety, speed and efficiency/cost advantages that make it the system of choice for rapid development and production of custom biological therapies and vaccines, especially in personalized medicine and emergency preparedness settings. Bacilligen is supported by NIH to develop a BVS-based HIV vaccine and has moved to apply the technology to other infectious diseases and cancer. rMB, also supported by an NIH award, will improve upon the safety and anticancer activity of the currently used BCG to permit more patients to benefit from mycobacteria immunotherapy.

Contact Information

  • Contact:
    Steve Bende, Ph.D.
    President & CEO
    Bacilligen, Inc.
    Email Contact

    Media Contact
    Michelle Ferrone
    Email Contact